Dewey M, Hamm B
Institut für Radiologie der Charité-Universitätsmedizin Berlin, Freie Universität und Humboldt-Universität zu Berlin.
Dtsch Med Wochenschr. 2004 Jun 18;129(25-26):1415-9. doi: 10.1055/s-2004-826875.
The cost-effectiveness of medical procedures is becoming a crucial factor besides their efficacy in clinical decision-making. We performed a cost-effectiveness analysis of the most common diagnostic modalities used in assessing coronary artery disease (CAD).
A decision tree model for determining the cost-effectiveness in CAD diagnosis was applied to the situation in Germany to calculate the cost-effectiveness of exercise ECG (ExECG), stress echocardiography (ECHO), myocardial scintigraphy (SPECT), and coronary angiography (ANGIO). The cost-effectiveness was defined as direct and induced costs per correctly identified patient. A sensitivity analysis was performed varying the predictive accuracies, the complication-related costs, and costs and complication rates of ANGIO.
The costs per correctly identified patient decreased in a hyperbolic fashion as the pretest likelihood of CAD increased due to the higher incidence of positive findings. For a pretest likelihood between 10 and 40%, ExECG and ECHO were most cost effective with costs per CAD patient of 5,880 - 2,500 EUR and 6,410 - 2,280 EUR, respectively. The combination of ExECG und ECHO (application of the second modality in case the first one was nondiagnostic) further improved the cost-effectiveness up to a pretest likelihood of 35%. For a pretest likelihood of 50% or greater, ANGIO costing 1,880 - 940 EUR per correct diagnosis was most cost-effective. Sensitivity analysis revealed no significant changes demonstrating the robustness of the model.
ANGIO is the most cost-effective procedure for a pretest likelihood of 50% or greater. At lower pretest likelihoods, ExECG, ECHO and the combined ExECG/ECHO strategy based on economic considerations are the preferred modalities for diagnosis of CAD.
在临床决策中,医疗程序的成本效益除了其疗效外正成为一个关键因素。我们对评估冠状动脉疾病(CAD)时最常用的诊断方法进行了成本效益分析。
将用于确定CAD诊断成本效益的决策树模型应用于德国的情况,以计算运动心电图(ExECG)、负荷超声心动图(ECHO)、心肌闪烁显像(SPECT)和冠状动脉造影(ANGIO)的成本效益。成本效益定义为每正确识别一名患者的直接成本和间接成本。进行了敏感性分析,改变了预测准确性、与并发症相关的成本以及ANGIO的成本和并发症发生率。
由于阳性结果的发生率较高,随着CAD的预测试验可能性增加,每正确识别一名患者的成本呈双曲线下降。对于10%至40%的预测试验可能性,ExECG和ECHO最具成本效益,每名CAD患者的成本分别为5880 - 2500欧元和6410 - 2280欧元。ExECG和ECHO联合使用(如果第一种方法无法诊断则应用第二种方法)在预测试验可能性达到35%之前进一步提高了成本效益。对于50%或更高的预测试验可能性,每次正确诊断成本为1880 - 940欧元的ANGIO最具成本效益。敏感性分析显示无显著变化,表明该模型具有稳健性。
对于50%或更高的预测试验可能性,ANGIO是最具成本效益的程序。在较低的预测试验可能性下,基于经济考虑,ExECG、ECHO以及ExECG/ECHO联合策略是诊断CAD的首选方法。